Legend Biotech's CAR-T Therapy Carvykti on Track to Surpass $2 Billion in Annual Sales Following Strong H1 2025 Performance

Jul 17, 2025 14:56 CST Updated 14:56

Legend Biotech

Tumor Cell Immunotherapy Developer

Johnson & Johnson

Medical Device R&D and Manufacturer

Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Feel free to point out in the comments. This article is only for the introduction of medical and health-related drugs, not a recommendation of treatment plans (if involved); this article does not constitute any investment advice.

Recently,Johnson & Johnson Announces 2025 H1 Results,Revenue in the first half of the year was $45.636 billion, a year-on-year increase of 4.1%. Notably,Co-developed with Legend BiotechBCMA CAR-T Cell Therapy Carvykti Achieves Notable Performance.

Carvykti's Sales Reach $808 Million in the First Half of 2025, Poised to Hit $2 Billion for the Full Year.

In 2024,CarvyktiNet trade sales for the year in China were approximately US$963 million.Carvykti's sales in 2023 reached 500 million US dollars.

Carvykti（Cilta-cel (generic name: ciltacabtagene autoleucel) is a CAR-T therapy targeting B-cell maturation antigen,For adult patients with relapsed or refractory multiple myeloma who have previously received treatment regimens including proteasome inhibitors, immunomodulatory agents, and anti-CD38 antibodies, and have experienced disease progression during or after their last treatment.

Carvykti was granted the first CAR-T clinical trial application approval by the China National Medical Products Administration in 2018. Since then, it has conducted clinical trials in multiple countries and regions worldwide, subsequently receiving various designations and approvals. On February 28, 2022, its U.S. marketing application was approved by the U.S. Food and Drug Administration; in May of the same year, the European Commission granted it conditional marketing authorization.

References: Public Reports